Table 1. Clinical characteristics of the study population (n=119).
| Characteristics | Number | Percentage (%) |
|---|---|---|
| Gender | ||
| Male | 83 | 69.75 |
| Female | 36 | 30.25 |
| Age (years) | ||
| ≤60 | 78 | 65.55 |
| >60 | 41 | 34.45 |
| Smoking status | ||
| No | 59 | 49.58 |
| Yes | 60 | 50.42 |
| Histology | ||
| Adenocarcinoma | 107 | 89.92 |
| Non-adenocarcinoma | 12 | 10.08 |
| ECOG PS | ||
| 0–1 | 97 | 81.51 |
| ≥2 | 22 | 18.49 |
| Clinical stage | ||
| IIIB | 11 | 9.24 |
| IV | 108 | 90.76 |
| Brain metastases before treatment | ||
| No | 87 | 73.11 |
| Yes | 32 | 26.89 |
| Bone metastases before treatment | ||
| No | 73 | 61.34 |
| Yes | 46 | 38.66 |
| EGFR exon 20 insert mutant group | ||
| A767_V769dupASV | 33 | 27.73 |
| S768_D770dupSVD | 19 | 15.97 |
| N771_H773dupNPH | 11 | 9.24 |
| A763_Y764insFQEA | 2 | 1.68 |
| Others | 54 | 45.38 |
| EGFR-TKI | ||
| No | 108 | 90.76 |
| Yes | 11 | 9.24 |
| First-line chemotherapy | ||
| Pemetrexed-based | 77 | 64.71 |
| Non-pemetrexed | 42 | |
| Second-line chemotherapy | ||
| Pemetrexed-based | 16 | 13.45 |
| Non-pemetrexed based | 103 | 86.55 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.